News: Adamas Enrollment for Parkinson Study $ADMS
Adamas Pharmaceuticals, Inc., has completed the recruitment of its Phase 3 EASE LID study. EASE LID is a confirmatory trial designed to evaluate the efficacy and safety of ADS-5102 for the treatment of levodopa-induced dyskinesia (LID), a motor complication associated with the treatment of Parkinson’s disease. “This important achievement brings us one step closer to our […]
News: Adamas Enrollment for Parkinson Study $ADMS Read More »